As one of the top 10 oncology companies in the world, Lilly Oncology focuses on speeding innovation and improving outcomes for individual patients, and boast one of the largest clinical pipelines in the oncology industry.
For more than four decades, Lilly has been dedicated to delivering innovative solutions that accelerate the pace and progress of cancer care and enhance the lives of people living with cancer.
We currently have three cancer medicines on the market. More information about these products can be found on the Lilly Oncology website.
Through our ongoing research efforts around the world, we invest significant resources in these products to help meet unmet medical needs, to better understand how our medicines work and to find out which patients are most likely to benefit from them.
For journalists looking for more information about Lilly Oncology, please visit the Lilly Oncology Newsroom, an expanded interactive online newsroom for media that features non-commercial, educational and scientific-based oncology information.
What Makes Us Unique
Today, Lilly Oncology has one of the most robust clinical stage pipelines in the industry. Included in our pipeline are both small molecules and biologics, which are being studied to treat a wide range of cancers.
For nearly all molecules in our pipeline, we have biomarker strategies targeting a genetic defect or genetic overexpression. These biomarkers help identify patients who have a higher likelihood of responding to treatment.
Today, Lilly Oncology continues to place a priority on speeding innovation that will improve outcomes for individual patients facing cancer. And because no two cancer patients are alike, we are committed to developing novel treatment approaches.
Our strategy is focused on delivering “tailored therapies” as one of the key ways to speed innovation and improve outcomes for individual patients. In doing so, we are finding ways to identify patients who are most likely to respond to therapy and just as importantly, which patients will not.